VBIO – Vitality BioPharma Inc

Between 10% to 15% of people in the world suffer from Irritable Bowel Syndrome…….



A number that is continually growing and today's treatments come with unwanted side effects, creating the environment for new developments in what is still considered "unconventional" but could be the future of medicine….



VBIO really does have advancements that could be the "future".

A Little About VBIO:
 
Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders.
 
We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as inflammatory bowel disease, narcotic bowel syndrome, and multiple sclerosis.  
 
In our programs, we aim to go beyond merely providing symptomatic relief to patients afflicted with these disorders, and to instead provide targeted therapies that can provide long-term or durable relief, as well as even help them recover lost function.
 
About Industry:
 
Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, some prodrugs may be approved rapidly through demonstrating similar bioavailability or bioequivalence.  
At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects.  In our case, targeted delivery could enable oral drug formulations of cannabinoids that provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream.  
 
A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid.  As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
 
One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 20 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.
 
Recent Developments:
 
 
LOS ANGELES, CA–(Marketwired – Aug 2, 2017) – Vitality Biopharma, Inc. ( OTCQB :VBIO ) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1 million private placement.
 
 
LOS ANGELES, CA–(Marketwired – Jul 19, 2017) – Vitality Biopharma, Inc. ( OTCQB :VBIO ) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.
 
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can be targeted and limited to the gastrointestinal tract, thereby avoiding drug psychoactivity and unforeseen side effects. In a preclinical model of inflammatory bowel disease (IBD), cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls. Vitality's cannabosides were successful in treatment of an acute model of colitis (DSS), which is traditionally viewed as very challenging, given that certain FDA-approved therapies including corticosteroids and TNF-alpha inhibitors have been shown to be ineffective for treating this model. The positive preclinical efficacy results with cannabosides are required in order for the Company to progress into first-in-man clinical trials.
 
The presense of a potential catalyst here is impecable, there is a reason why VBIO is trading over a dollar!

Keep in mind, pharam plays recently have become like the old days of mining companies in the OTC world, no cash, borrowed assets, no reveneus, yet 10 times valutions…...it is unreal.

VBIO has revenues, fully reporting, three star rating and making advancements in the sector of the medical world that does not yet really exist. But that is where those who have the mindset invision the future, and create the science that froms into a new standard in the future.

Please, I urge you to start you research on VBIO right away and enjoy.

Sincerely,

AST

Disclaimer:

We have received seven thsnd dlrs via a bank wire for the awereness of VBIO.
 

All of the information in this blog is gathered from public information released by the company.

By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.



We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.


Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

 

 

Leave a Reply